Dr Reddys Laboratories announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the U. S.
Food and Drug Administration (USFDA) via a 505(b)(2) new drug application (NOA) pathway for intravenous use only.
Dr. Reddy's Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)